VRT-043198

VRT-043198

• CAS Number: 244133-31-1
• UNSPSC Description: VRT-043198, the agent metabolite of VX-765 (Belnacasan), is a potent, selective and blood-brain barrier permeable inhibitor of interleukin-converting enzyme/caspase-1 subfamily caspases. VRT-043198 exhibits Ki values of 0.8 nM and 0.6 nM for ICE/caspase-1 and caspase-4, respectively[1].
• Target Antigen: Caspase; Drug Metabolite
• Type: Reference compound
• Related Pathways: Apoptosis;Metabolic Enzyme/Protease
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/vrt-043198.html
• Purity: 98.89
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(N[C@H](C=O)CC(O)=O)[C@H]1N(C([C@H](C(C)(C)C)NC(C2=CC=C(N)C(Cl)=C2)=O)=O)CCC1
• Molecular Weight: 480.94
• References & Citations: [1]Woods Wannamaker, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007 May;321(2):509-16.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported